ANN ARBOR, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that it intends to offer and sell, subject to market and other conditions, $85 million of its common stock in an underwritten public offering. Esperion expects to grant the underwriters a 30-day option to purchase up to $12.8 million of additional shares of its common stock.
Help employers find you! Check out all the jobs and post your resume.
